Trial Profile
A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to <18 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Seqirus
- 28 Dec 2021 Results published in the JAMA: the Journal of the American Medical Association
- 14 Oct 2021 Results published in the New England Journal of Medicine
- 14 Oct 2021 According to a Seqirus media release, data from this study was published in The New England Journal of Medicine.